Metastatic Solid Tumors Clinical Trial
Official title:
A Phase I Open-label Dose Escalation Study of AT13387 in Patients With Metastatic Solid Tumors
AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with the protocol increasing doses of AT13387 are given to patients with advanced cancer who do not have alternative treatment options. The preferred dose of AT13387 will be identified according to the side effects experienced at different dose levels.
Increasing doses of AT13387 will be administered to groups of 3 to 6 patients at each dose level. The pharmacokinetic profile of AT13387 following a one hour intravenous infusion will be determined and the effect of AT13387 on predefined biomarkers in blood plasma and circulating white blood cells will be established. Patients will be closely monitored for the development of side effects which would preclude further dose escalation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03993873 -
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05494918 -
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
|
Phase 1 | |
| Completed |
NCT02281409 -
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01928459 -
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
|
Phase 1 | |
| Completed |
NCT01449370 -
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT06031441 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03059823 -
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03573544 -
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03893955 -
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT00149019 -
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
|
Phase 2 | |
| Recruiting |
NCT03093116 -
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
|
Phase 1/Phase 2 | |
| Terminated |
NCT03854227 -
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04094610 -
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01543763 -
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02228811 -
A Study of DCC-2701 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05853367 -
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
|
Phase 1 | |
| Completed |
NCT02097810 -
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
|
Phase 1 | |
| Recruiting |
NCT05836324 -
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03910530 -
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT00148993 -
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
|
Phase 1/Phase 2 |